Neuropathic Corneal Pain (NCP) Market: Current Scenario & Momentum Building Toward 2036 | Thelansis

New Thelansis Report Charts Epidemiology, Competitive Landscape and Market Forecast (2026-2036) for a Long-Overlooked Ocular Pain Disorder

Neuropathic Corneal Pain (NCP) is finally getting the attention it has long deserved. Once dismissed as an extension of dry eye disease, NCP is increasingly recognized by ophthalmologists and pain specialists as a distinct, chronic condition rooted in corneal nerve injury and dysfunction, one that leaves patients in persistent discomfort with few effective treatment options.
Thelansis Knowledge Partners has released its latest syndicated report, "Neuropathic Corneal Pain (NCP): Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036)," offering biopharma leaders, market access teams, and investors a data-backed view of where this niche but fast-evolving therapy area is heading.

Request a free sample of Thelansis' Neuropathic Corneal Pain (NCP) Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/neuropathic-corneal-pain-ncp-market-outlook-forecast-2026-to-2036/

Executive Summary
NCP sits at the intersection of ophthalmology and chronic pain management, and it is no longer flying under the radar. Historically underdiagnosed and frequently confused with dry eye disease, NCP is now being reframed as its own orphan indication, helped along by regulatory milestones, sharper diagnostic tools, and a slowly maturing pipeline.
• Classified as an orphan disease: NCP still lacks a single FDA-approved, disease-specific therapy, leaving a meaningful white space for first movers.
• Regulatory momentum is building: the first IND clearance specifically for an NCP-targeted therapy arrived in 2024, followed by Fast Track designation in 2025 - both signals that regulators see urgency here.
• Diagnosis is improving: wider use of in vivo confocal microscopy and corneal nerve imaging is helping clinicians finally distinguish NCP from nociceptive dry eye, which should translate into better patient counts and earlier intervention.

Thelansis report unpacks all of this: epidemiology, treatment patterns, emerging pipeline, and a 2026-2036 forecast giving decision-makers a single reference point for an indication that is easy to underestimate and hard to research well.

Key Emerging Players
The NCP pipeline remains thin, which is exactly what makes the few active programs so important to track.
• OKYO Pharma - urcosimod (formerly OK-101): a chemerin-receptor targeting therapy designed to modulate the immune and neuronal pathways behind corneal nerve pain. It received IND clearance in February 2024 and FDA Fast Track designation in April 2025, positioning it as the most advanced NCP-specific candidate today.
• Bausch + Lomb / Novartis - SAF312 (libvatrep): an ion-channel modulator that changed hands as part of a large front-of-eye ophthalmology asset transfer; its future development path remains unclear, underscoring how fluid the competitive field still is.
• Adjacent innovators: companies working on corneal neurostimulation, regenerative nerve-repair approaches, and precision ocular diagnostics are also shaping how NCP will eventually be managed, even where NCP isn't their primary indication.

Because so few assets are purpose-built for NCP, even incremental pipeline movement can meaningfully shift competitive dynamics, something the full Thelansis competitive landscape chapter tracks in detail.

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Neuropathic Corneal Pain (NCP): https://thelansis.com/reports/neuropathic-corneal-pain-ncp-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ncp_mo

Key Current Therapies & Standard of Care
In the absence of an approved, targeted NCP therapy, management today is largely a matter of adapting tools built for other ocular conditions.
• Topical anesthetics (lidocaine, tetracaine) - offer short-term numbing relief but do not address underlying nerve dysfunction.
• Nerve growth factor (NGF) therapy (e.g., cenegermin) - supports corneal nerve healing, originally developed for neurotrophic keratitis but explored for broader neuropathic applications.
• Off-label systemic agents - antidepressants like amitriptyline and anticonvulsants like gabapentin are used for their central pain-modulating effects, borrowed directly from chronic pain medicine.
• Supportive care - autologous serum eye drops, lubricants, and emerging neurostimulation techniques (including intense pulsed light) help manage symptoms but rarely deliver durable relief.

The consistent theme: everything currently in use is repurposed, and most options provide partial or temporary relief at best, which is precisely the gap the emerging pipeline is trying to close.

Key Market Drivers & Trends
• Diagnostic clarity is accelerating case identification: in vivo confocal microscopy and corneal nerve imaging are helping separate true NCP from dry eye and other ocular surface disease, a shift that's expanding the visible, addressable patient pool.
• Precision medicine is entering ophthalmology: treatment strategies are increasingly being tailored to individual corneal nerve profiles rather than applied as one-size-fits-all.
• Regulatory tailwinds: Fast Track designation and orphan-disease recognition are shortening development timelines and signaling to investors that this indication is gaining institutional credibility.
• Investor and R&D interest in non-opioid pain relief: with ophthalmology start-ups continuing to attract equity funding, targeted, non-opioid modulators for ocular pain are becoming a more visible investment theme.
• Aging population: as elderly populations grow globally, the burden of chronic ocular surface and nerve-related pain conditions is expected to rise in parallel.

Together, these forces are moving NCP from a niche, misunderstood condition toward a defined, investable therapy area - and the Thelansis 2026-2036 forecast models exactly how that shift plays out across major markets.

Translate these macro drivers into a competitive advantage. Request the Thelansis Neuropathic Corneal Pain (NCP) sample report to unlock granular pipeline analysis, deal tracking, and market forecasts: https://thelansis.com/reports/neuropathic-corneal-pain-ncp-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ncp_mo

Key Unmet Need & KOL Expectations
Ask any cornea specialist or pain physician working with these patients, and the same frustrations surface repeatedly.
• No approved, disease-specific therapy exists: clinicians are left combining off-label systemic drugs and supportive measures, with inconsistent results.
• Misdiagnosis remains common: NCPs' overlap with dry eye disease means many patients cycle through ineffective treatments before receiving an accurate diagnosis.
• Patient burden is underestimated: photoallodynia, burning, and persistent discomfort are frequently dismissed as psychosomatic, particularly given the higher prevalence of NCP among women with comorbid anxiety, depression, or fibromyalgia.
• KOLs are asking for: validated diagnostic criteria, therapies that target nerve pathophysiology rather than symptoms alone, and greater clinical education to legitimize NCP as a distinct diagnosis worthy of dedicated care pathways.

These unmet needs are exactly why an evidence-based, regularly updated market and epidemiology view matters; it gives stakeholders a credible foundation for pipeline, access, and investment decisions.

Commercial Opportunity
For biopharma companies, investors, and market access teams, NCP represents a rare combination: a clearly underserved, orphan-designated condition with an emerging, not overcrowded, competitive field.
• First-mover advantage: with no approved, disease-specific therapy on the market, an approved product would enter with limited direct competition and immediate KOL attention.
• Orphan and Fast Track incentives: regulatory pathways already in motion can meaningfully compress time-to-market for well-positioned candidates.
• Expanding, better-characterized patient population: improved diagnostics mean the addressable market is likely larger, and more identifiable, than historical estimates suggest.
• Cross-market opportunity: The Thelansis report models epidemiology and forecast trends across major markets, helping companies prioritize launch sequencing and access strategy.

Thelansis 2026-2036 report is built to support exactly these decisions combining epidemiological modeling, competitive intelligence, and forecast data into a single, decision-ready resource for teams evaluating entry, partnership, or investment in the NCP space.

Access the complete Neuropathic Corneal Pain (NCP) market outlook and forecast report to explore the evolving market and future commercial opportunities: https://thelansis.com/reports/neuropathic-corneal-pain-ncp-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ncp_mo

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.